EU panel recommends expanded use of DMD treatment Agamree
WHY IT MATTERS
This expanded approval could allow children with DMD as young as age 2 to start Agamree treatment earlier, potentially slowing muscle weakness progression during critical early development years.
A European health committee has recommended that Agamree, a medicine for Duchenne muscular dystrophy (DMD), be approved for use in younger children starting at age 2. Previously, the drug was approved for older children and adults. This recommendation means more DMD patients in Europe could potentially access this treatment if the European Medicines Agency approves the committee's suggestion.
The Committee for Medicinal Products for Human Use (CHMP) has recommended that approval of Agamree (vamorolone) in the European Union be expanded to include people with Duchenne muscular dystrophy (DMD) as young as 2. The CHMP is an arm of the European Medicines Agency (EMA) tasked with reviewing data on experimental therapies. The committee’s recommendation […] The post EU panel recommends expanded use of DMD treatment Agamree appeared first on Muscular Dystrophy News .
ASK YOUR DOCTOR
If your child has DMD and is under age 5 in Europe, ask your neurologist whether Agamree might be appropriate once the EMA formally approves this age expansion.